SCHEMBL8524381

SCHEMBL8524381

O=CNCCN(CC(F)(F)F)C(=O)C1c2ccccc2-c2cccc(N3CCC(NC(=O)c4ccccc4Oc4ccccc4)CC3)c21

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CCR3 P51677 4/20 0.42
▸ HPGDS O60760 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ SLC6A12 P48065 1/20 0.34
▸ HTR7 P34969 3/20 0.34
▸ HTR1A P08908 2/20 0.34
▸ DRD2 P14416 2/20 0.34
▸ HTR6 P50406 2/20 0.34
▸ KDM5A P29375 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ CNR1 P21554 1/20 0.32
▸ CNR2 P34972 1/20 0.32
▸ PTGDR2 Q9Y5Y4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8666998 0.96 CCR3 (0.40) CCR3HPGDSKDM4EMEN1KMT2A
SCHEMBL8717983 0.90 CCR3 (0.43) CCR3HPGDSKDM4EMEN1KMT2A
SCHEMBL8712537 0.90 CCR3 (0.43) CCR3HPGDSKDM4EMEN1KMT2A
SCHEMBL8717870 0.89 NPSR1 (0.38) CCR3MEN1KMT2ASLC6A12DRD2
SCHEMBL8665515 0.86 CCR3 (0.41) CCR3KDM4ESLC6A12HTR7HTR1A
SCHEMBL8665525 0.85 CCR3 (0.40) CCR3KDM4ESLC6A12HTR7HTR1A
SCHEMBL8665477 0.85 DRD2 (0.37) CCR3DRD2NPSR1
SCHEMBL8485533 0.80 NPSR1 (0.42) CCR3MEN1KMT2ASLC6A12DRD2
SCHEMBL8653114 0.80 CCR3 (0.42) CCR3HPGDSKDM4EMEN1KMT2A
SCHEMBL8484454 0.80 NPSR1 (0.42) CCR3MEN1KMT2ASLC6A12DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5883099-A TREATMENT OF ATHERSCLEROSIS, PANCREATITIS OBESITY OR HYPERGLYCEMIA BRISTOL-MYERS SQUIBB COMPANY (US) 1999-03-16 — — US disclosed
US-5739135-A PREVENTING OR TREATING ATHEROSCLEROSIS, PANCREATITIS SECONDARY TO HYPERTRIGLYCERIDEMIA, HYPERGLYCEMIA, OBESITY BRISTOL-MYERS SQUIBB COMPANY (US) 1998-04-14 — — US disclosed
Send feedback